septacidin has been researched along with krn 5500 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujisawa, S; Luo, JM; Maksumova, L; Muratkhodjaev, F; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Pan, L; Shigeno, K; Shinjo, K; Takeshita, A; Yoshida, H; Zhang, WJ | 1 |
| Mizumura, Y | 1 |
1 review(s) available for septacidin and krn 5500
| Article | Year |
|---|---|
[Spicamycin derivative].
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Humans; Micelles; Polymers; Purine Nucleosides; Rats | 2006 |
1 other study(ies) available for septacidin and krn 5500
| Article | Year |
|---|---|
Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein.
Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Differentiation; Cell Survival; Down-Regulation; Hematopoietic Stem Cells; HL-60 Cells; Humans; Neoplasm Proteins; Nuclear Proteins; Promyelocytic Leukemia Protein; Proto-Oncogene Proteins c-bcl-2; Purine Nucleosides; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2000 |